Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences Corp, filed a Form 4 on November 9, 2026, reporting the exercise of stock options and the sale of 48,900 shares of common stock on that same date under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Bobo acquired 48,900 shares of common stock on November 9, 2026, via the exercise of employee stock options at a conversion price of $72.68 per share.
- Shares sold: All 48,900 acquired shares were disposed of on November 9, 2026, at a weighted average sale price of $103.0534, with individual trade prices ranging from $103.00 to $103.19.
- Post-transaction direct holdings: Following the transactions, Bobo directly held 22,798.2532 shares of common stock.
- Indirect holdings: The filing also reports 30,969.5756 shares held indirectly through a 401(k) plan and 98,611 shares held indirectly by trust.
- 10b5-1 plan: According to the filing, the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Bobo on February 12, 2026.
- Options fully exercised: The employee stock option (exercisable from June 7, 2020, expiring May 6, 2027) shows zero derivative securities remaining following the transaction.
Bobo's November 2026 Option Exercise and Share Sale at Edwards Lifesciences
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Donald E. Bobo Jr., identified in the filing as Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences Corp (NYSE:EW), reported two non-derivative transactions and one derivative transaction all occurring on November 9, 2026. The filing was submitted by Linda J. Park as attorney-in-fact on the same date.
The filing discloses that Bobo exercised employee stock options carrying a conversion price of $72.68 per share, acquiring 48,900 shares of common stock. Those same 48,900 shares were then sold at a weighted average price of $103.0534. The filing notes that the sale "was executed in multiple trades at prices ranging from $103.00 to $103.19," and that Bobo "undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected." After these transactions, Bobo's directly held common stock position stood at 22,798.2532 shares.
Both the option exercise and the share sale are listed in the filing as transaction code "M" and "S," respectively, and are indicated as having been made pursuant to a Rule 10b5-1 contract, as shown by the checked box on the form. The trading plan was adopted on February 12, 2026, according to the explanation of responses. The filing also notes: "This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person."
What Was Disclosed
The filing reports a same-day option exercise and sale of 48,900 Edwards Lifesciences common shares by CVP Donald E. Bobo Jr. on November 9, 2026, executed under a pre-established 10b5-1 plan, with direct holdings reduced to 22,798.2532 shares afterward.




Please wait processing your request...